The Society for
Functional Precision Medicine

Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.


Membership

The SfPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits

  • SfPM members in good standing (dues paid through Dec. 31, ) are eligible for self nominations in our monthly seminars
  • Exclusive access to our biannual newsletter curated by our board with articles, news and insights about the world of functional precision medicine.
  • A members exclusive directory with information on research interests and home institutions to facilitate collaboration and networking
  • Facilitate trainee placements in post-doc and industry settings by recognizing shared interests and partnerships
  • Free registration for SfPM Annual Meetings and special conferences
  • Access to recordings of our virtual meetings along with contact information of speakers to connect with
  • Many more ongoing benefits

Applications for membership may be submitted at any time during the year. We look forward to having you onboard!

  Become a Member


Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Next Seminar |
Wednesday, March 10, 2021 at 11:00 AM EST

https://dfci.zoom.us

Meeting ID: 936 9981 1786
Password: 351904

 Learn More   Register

Featured Speakers

Diana Azzam, PhD
Diana Azzam, PhD
Robert Stempel College of Public Health & Social Work

“Clinical Utility of Functional Precision Medicine in the Management of Relapsed/Refractory Childhood Cancers”


Razelle Kurzrock, MD
Razelle Kurzrock, MD
UC San Diego

“Precision Medicine: Implementing N-of-1 combination therapies in the clinic”



Recent News

Two postdoc positions in computational cancer biology at NTNU
JANUARY 28, 2021
Two postdoc positions in computational cancer biology at NTNU

Are you a computational biologist or bioinformatician eager to apply your skills and ingenuity to tackle cancer? We open two postdoc researcher positions at NTNU as part of our ERA PerMed project ONCOLOGICS. The two appointed postdocs will work in close collaboration with each other and with a large research team from leading European research organizations.

Learn More


Plenary Sesion - A podcast on medicine, oncology, & health policy
OCTOBER 22, 2020
Plenary Sesion - A podcast on medicine, oncology, & health policy

Dr Anthony Letai sits down with Dr Vinay Prasad for a an episode of Plenary Session where Dr Letai speaks about precision oncology, the Match trial and NGS in cancer. Be sure to check it out!

Learn More


Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
AUGUST 17, 2020
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse.

Learn More


Tumor Organoids for Functional Precision Oncology
JULY 15, 2020
Tumor Organoids for Functional Precision Oncology

Researchers are using patient-derived tumor organoids to match patients with optimal treatments - When most people think of precision cancer medicine, they think of genomics, with researchers trying to decipher complex gene interactions for the clinical benefit of patients. But according to Dr. Christopher Kemp, a cancer biologist at the Fred Hutchinson Cancer Research Center, that is a narrow view: “[Genomics] is important, but it’s not the whole puzzle by any stretch.”

Learn More


Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD
JUNE 29, 2020
Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD

Anthony Letai, PhD gives an overview of how BH3 profiling can be used to predict response to therapy. “There is an enormous amount of actionable information that can be obtained from taking the actual cancer cell you’re interested in and subjecting it to a relevant perturbation, that is, exposing it to the actual drugs,” he said. “We nearly completely overlook this in today’s precision medicine approaches, and I think there is enormous unrealized potential in this general approach.”

Learn More


ALL NEWS